Blood clot risk higher for six months after having COVID-19
April 7, 2022Business Services
A study from Sweden suggests that after a COVID-19 infection, there is an increased risk of developing a serious blood …
Eligible patients in the UK granted early access for radioligand therapy in advanced prostate cancer
April 7, 2022Business Services
Advanced Accelerator Applications (AAA), a Novartis company, has announced that eligible patients in the UK have been granted early access …
Global Paediatric Drug Development Centre of Excellence opened in Dublin’s North Dock
April 7, 2022Business Services
Gilead Sciences announced on April 6th the formal opening of its Dublin city centre office, focused on developing new paediatric …
Nine more COVID-19 symptoms added to list
April 6, 2022Research and Development
Nine new symptoms, including sore throat, fatigue, and headache, have been added to the official list of COVID-19 symptoms on …
UK Government accused of failing to address cancer staff shortages
April 6, 2022Research and Development
MPs have warned that urgent steps are needed to prevent the UK from losing gains made in recent years on …
New variant, Omicron XE, detected in UK
April 6, 2022Research and Development
A new sub-variant of Omicron has been found in the UK, as the country experiences a new surge of COVID-19.The …
Race to deliver HIV drugs to Ukraine
April 6, 2022Research and Development
WHO is to supply thousands of antiretroviral drugs to Ukraine for patients living with HIV over the next year. UNAIDS, …
European Commission approves treatment of unresectable uveal melanoma
April 5, 2022Manufacturing and Production
Immunocore Holdings has announced that the European Commission has approved KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adult patients with …
Technology enabling thermally-controlled DNA synthesis
April 5, 2022Manufacturing and Production
Evonetix has been granted a patent in Europe for thermal control technology for DNA synthesis, as well as the design …
NHS struggling to make progress on early cancer diagnosis
April 5, 2022Manufacturing and Production
MPs have warned that the NHS in England is struggling to make progress on its flagship target to diagnose three-quarters …
FDA approves generic version of brain imaging agent in US
April 5, 2022Manufacturing and Production
The FDA has approved the generic version of DaTscan (Ioflupane I 123), manufactured and commercialised by Curium. This is a …
FlyPharma Conference Europe: New dates and location announced
April 4, 2022Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
FlyPharma Conferences are pleased to announce that FlyPharma Europe is returning as a live, in-person event in 2022.
AI test could predict effective cancer drug combinations in less than two days
April 4, 2022Sales and Marketing
Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in …
FDA accepts Dupixent for Priority Review in patients 12+ with eosinophilic esophagitis
April 4, 2022Sales and Marketing
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab), in patients aged 12 …
New centre targets ‘undruggable’ cancers
April 4, 2022Sales and Marketing
The new Centre for Protein Degradation has been launched, made possible by a £9 million donation to The Institute of …
COVID-19 vaccines now available for five to 11-year olds in England
April 4, 2022Sales and Marketing
Parents and carers of five to 11-year olds in England can now book a low-dose COVID-19 vaccine for their children. …
FDA places two clinical holds on CytoDyn HIV and COVID-19 programmes
April 1, 2022Medical Communications
The FDA has placed a partial hold on CytoDyn’s HIV program, and a full clinical hold on its COVID-19 program …
Biomodex launches clear cartridges for neurovascular training
April 1, 2022Medical Communications
Biomodex has announced the launch of clear cartridges for use with Biomodex’s EVIAS and EVIAS Plus stations.The cartridges are 3D …
Isturisa effective in treating rare Cushing’s disease
April 1, 2022Medical Communications
Recordati Rare Diseases has announced the publication of positive results from the Phase III LNC 4 study, confirming the efficacy …
UK app launched for people living with glaucoma
April 1, 2022Medical Communications
Santen UK has launched a new app for people living with glaucoma, in partnership with Glaucoma UK, the leading charity …
